Clinical Trial Update: LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI) [Phase 2]

View source ↗

Summary

Phase 2 trial update for LYS228 in complicated intra-abdominal infection (cIAI) evaluating pharmacokinetics, clinical response, safety and tolerability; study t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Intra-abdominal Infection

Drugs mentioned

• LYS228

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Intra-abdominal Infections | Phase 2 | Status: TERMINATED | Results posted: 2019-10-08